anaplastic large cell lymphoma, ALK-negative
GPTKB entity
Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:associated_with |
C D30 positivity
|
| gptkbp:can_lead_to |
secondary malignancies
|
| gptkbp:has_style |
gptkb:ALK-negative_anaplastic_large_cell_lymphoma
|
| https://www.w3.org/2000/01/rdf-schema#label |
anaplastic large cell lymphoma, ALK-negative
|
| gptkbp:is_associated_with |
gptkb:fandom
thrombocytopenia poor prognosis lymphocytosis elevated LDH levels |
| gptkbp:is_characterized_by |
genetic mutations
tumor microenvironment chromosomal abnormalities cytokine production immune evasion increased proliferation large atypical lymphoid cells C D4 positive T-cells C D8 positive T-cells expression of activation markers inflammatory microenvironment loss of T-cell markers |
| gptkbp:is_monitored_by |
gptkb:MRI
CT scan PET scan |
| gptkbp:is_often_used_in |
gptkb:Person
adults |
| gptkbp:is_part_of |
oncology
hematology cancer research lymphoma classification |
| gptkbp:is_related_to |
gptkb:healthcare_organization
|
| gptkbp:is_studied_in |
clinical trials
|
| gptkbp:is_used_for |
weight loss
fever night sweats lymphadenopathy |
| gptkbp:occurs_in |
gptkb:skincare_product
lungs bone marrow lymph nodes |
| gptkbp:scientific_classification |
hematologic malignancy
|
| gptkbp:social_responsibility |
biopsy
immunohistochemistry |
| gptkbp:treatment |
gptkb:hospital
gptkb:brentuximab_vedotin radiation therapy chemotherapy targeted therapy stem cell transplant hematologist |
| gptkbp:type_of |
gptkb:non-Hodgkin_lymphoma
|
| gptkbp:bfsParent |
gptkb:ALK
|
| gptkbp:bfsLayer |
5
|